Big pharma is discovering that one of most important factors to accelerate the pace of drug development is to reduce the physical distance between internal R&D labs and external partners. Consequently, most have set up R&D hubs close to ground zero of drug discovery – in major U.S. cities with important academic and medical centers that boast a highly skilled work force and access to risk capital. Read More
There is no doubt that investors have shrugged off their usual capital market summer blahs to keep a close eye on the biotech sector. Overall they have liked what they have seen with biotech's leading companies benefitting from that enthusiasm, seeing their share prices soar. During that period, the BioWorld Biotech Blue Chip index hit a new high for the year, thanks to its strong 10 percent jump in value in August. Read More
Biotechnology is no stranger to the creation and analysis of large amounts of data, whether it is "-omics" in nature or from patients in clinical trials. However, having access to masses of datasets is only a good starting point; sooner or later actionable information will need to be drawn from those resources. Read More
